The treatment of viral diseases caused by herpes virus


(57) Abstract:

The invention relates to medicine, in particular to the treatment of viral diseases caused by herpes virus. As antiherpetic tools used para-aminobenzoic acid. The drug is effective in the treatment of herpetic lesions of different localization.

The invention relates to medicine, in particular to the treatment of viral diseases caused by herpes virus.

Known used in the clinic specific protivoepilepticheskie drugs. These include desoksiribonukleaza. However, experimental antiviral effect dnaase in clinical application has not brought the desired results.

In addition, clinic 5-iodine-2-deoxyuridine that because of toxicity is not injected under the conjunctiva, and used in the form of drops. The use of drops of this drug for more than 10 days can have toxic effects on the epithelium of the cornea and conjunctiva, causing the phenomenon of follicular allergic conjunctivitis, point keratitis even development phenomena micropause. So even with good portability is not recommended to use this drug content exceeding 1).

Known para-aminobenzoic acid PABK (vitamin H1), which is used to increase yields of some crops, and also in perfumery as additives in creams and lipstick to protect skin from the damaging effects of UV rays as a screening non-toxic substances. Before the discovery of antibiotics PABK was a cure for typhus and ricketsiosis.

Although PABK known since the beginning of the twentieth century and in recent years found many positive qualities, it is in medicine wide application not found (2).

The task of the invention to expand the range of tools for the treatment of viral diseases caused by herpes virus, do not have negative effects, i.e. non-toxic for the human body.

The problem is solved by the fact that as a means for treating diseases caused by herpes virus, was used para-aminobenzoic acid (PABK).

Para-aminobenzoic acid (PABK) has the following structure C7H7NO2M m 137,15.

< / BR>
represents a connection with a broad spectrum of biological activities. PABK is a natural compound found in big is the use of synthetic PABK. PABK is vitamin H1and is part of the folic acid molecule (group of vitamins), as well as in a large number of other studied biological compounds and is physiologically active metabolite.

Numerous physiologically active derivatives PABK are used as anesthetics (procaine, benzocaine), gipolipidemicheskie and other means. With the introduction of novocaine in the internal environment of the body it breaks down into PABK and Diethylaminoethanol, which has only a vasodilator effect. PABK breaks in the body of the composition of novocaine, behaves as an active physiological connection. PABK is not a mutagen, moreover PABK possesses antimutagenic properties, dramatically increasing the efficiency of DNA repair after action supermutagenov.

PABK has the properties of a powerful reparagen, restoring the genetic structure of bacterial cells after exposure to ionizing radiation. Known for the ability PABK to regulate the activity of vital enzymes, restoring their activity after exposure to heat shock, ultraviolet and ionizing radiation. In particular PABK can increase activestatus herpetic keratitis, adenovirus lesions and others. From this we see that PABK as a medicinal agent for viral diseases can mobilize the activity of the endogenous enzyme systems of the tissues in the fight against viral infection.

In vitro experiments it is shown that PABK has a strong vermicidal effect on herpes simplex virus (WFP-T, L2). Contact PABK with HSV in the medium Needle for 90 minutes at a temperature of 20oWith the observed dose-dependent reduction in infectious titer. With a maximum dose of 20000 μg/ml difference with the control was 3.5 lg TC D50.

The efficiency PABK in experimental genericsoma encephalitis white mice. Mice intraperitoneally infected culture HSV-1, L2in the dose of 10 LD50/0,2 ml After 4 h after infection has begun to enter PABK (intraperitoneally, at a dose of 5 mg/kg). The injection was done daily for four days. Mortality in experimental mice was decreased by 30% compared with control. PABK also extended the life expectancy of infected mice at 4 days compared with the control. PABK, applied in an effective therapeutic dose, on day 8 after infection reduced the reproduction of HSV-1 in holosericea during clinical trials of the drug. Preliminary clinical trials have shown positive results.

The treatment is carried out as follows: for patients with appropriate diagnosis was introduced in the form of instillation in konyunktivalny bag and podklyucheniya injection solution PABK in physiological solution at concentrations of 2 to 10-3510-3% depending on the severity and course of the disease instillation was administered from 3 to 8 times per day; and an injection under the conjunctiva 1 time per day 0.2 to 0.4 ml of the same concentration to the disappearance of clinical symptoms, then treatment in the form of backfilling continued for 7-10 days 2-4 times a day.

Those patients who had a protracted course of the disease and directly before that were treated 2-3 months known specific anti-virus and nonspecific drugs, at the beginning of treatment PABK were cryoapplication the affected cornea. During treatment PABK took no other specific antiviral drugs.

Example 1. Female 35 years old with a diagnosis of primary herpetic tree keratitis in the right eye. The eye condition: expressed mixed conjunctival injection, expressed corneal syndrome. The cornea is edematous, in the center of the horns of the instillation received a 0.002% solution PABK within 12 days 6-8 times, in the following days before discharge 4-6 times a day, then after the statement was received within a week 2-3 times a day. Other specific antiviral drugs are neither local nor General did not. On the 6th day of the fluorescent probe was negative, with 5-day noted the positive dynamics of all symptoms. On the 12th day of the disappeared corneal edema. On the 19th day of discharge eye of calm in the centre of the cornea there is little cloud opacity. Vis. 0,8 n/K.

Example 2. Female 40 years with a diagnosis of recurrence of herpetic keratouveitis. The primary disease was 4 years ago, and as a result have remained moderate corneal opacity. Complaints of photophobia and moderate pain in the eye, weak, watery eyes. In the centre of the superficial layers of the cornea slightly swollen. Moderate conjunctival hyperemia. Vis. 0.1 g/K. the Patient received in the form of instillation of 0.002% solution PABK 3 times a day during the week. On the 5th day of the disappeared all symptoms: tearing, corneal edema. Vis. 0,4 n/K. in Addition PABK the patient received no other medications.

Example 3. The boy is 7 years with a diagnosis of primary materpiece keratitis in the right eye. Before entering unsuccessfully treated for the specific month (pyrogens locally and overall, IDU 1% and Drahovice, covering 1/3 of the cornea in the lower temporal sector (between 4-7 hours), reaching the edge of the pupil. Expressed mixed conjunctival hyperemia with swelling. Pronounced corneal syndrome (lacrimation, photophobia, severe pain in the eye). Biomicroscopy of the detected defects in the corneal epithelium, the cornea rough, intense blushing deeper layers of the stroma. Within 3 days of observation before treatment degeneration of the cornea quickly progressed to the center. After triplicate with simultaneous instillation PABK (0,002% ) 4-6 times a day on day 3 positive dynamics of all symptoms, fluorescent sample was negative (complete epithelialization of the cornea). On the 10th day from the start of treatment with the extract, eyes calm, almost transparent cornea. Vis. 0,9 n/K.

Example 4. Male 37 years. The diagnosis of primary protracted form of herpetic keratouveitis. Mixed pericorneal injection and conjunctival edema, pronounced corneal syndrome affected 2/3 of the cornea (the upper and outer part) places marked erosion, corneal edema and upper layers of the stroma. The cornea was riddled with newly formed vessels. The iris as a result of swelling blurred. Changed structure of the vitreous body. Had Azi and podklyucheniya injection, pyrogenes parenteral scheme and locally, antiherpetic gamma globulin topically, vitamin b2and other (within 25 days the patient was cryoapplication with simultaneous instillation of 0.005% PABK. Patient due to neovascularization of the cornea appointed as instillation of 1% emoxipin 3-4 times a day. On the 3rd day of corneal fluorescein test negative, positive dynamics of all symptoms. After 10 days from the beginning of our treatment of the eyes of calm, there is no peritoneally injection, the cornea is almost transparent, there was a regression of blood vessels to the level of the limbs, tziklicheskih no pain. Vis. 0.1 g/K. 10 days after the end of treatment due to hypothermia, the patient was treated with exacerbation of the disease: severe corneal syndrome, corneal edema, severe pain in the eye, expressed ciklicheskaja pain. The patient after the request was made podklyuchenie injection of 0.3 ml of 0.02% solution PABK and he was received in the form of drops in the conjunctival SAC 6-8 times a day solution PABK the same concentration. At night the patient was taking pain medication. With 3-day treatment of pain in the eye decreased, the patient stopped taking pain pills and noted n the days. After 15 days of calm eyes, the cornea is almost transparent. Vis. 0.1 g/K. the Recommended subsequent backfilling within 10 days 2-3 times a day.

All treatment received 19 patients, all 19 people there was an improvement in the condition of your eyes and the disappearance of symptoms within 3 weeks. During the year in the observed patients had no relapse, all patients had the condition of comfort in the eye from the first days of treatment PABK. No cases of intolerance to the drug or other adverse reactions were observed.

The use of para-aminobenzoic acid as a tool for the treatment of viral diseases caused by herpes virus.


Same patents:

The invention relates to chemical-pharmaceutical industry, in particular, to methods for drugs, namely paracetamol, intended for the treatment of gout, migraines, and also used as an analgesic and antipyretic
The invention relates to medicine, namely to Oncology, and can be used in the treatment of locally spread of malignant tumors
The invention relates to medicine, namely to antibioticotherapy inflammatory, infectious and neoplastic diseases

The invention relates to the medical industry, in particular, to the manufacture of drugs used in the treatment of headache, neuralgia and colds

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes new tablets with size less 3 mm with sustained-releasing the opioid analgesic drug for 30 min in the amount above 75%. Invention provides opioid for oral intake with taking into account individual necessity of patient due to selection of required amount of mictotablets by dispenser.

EFFECT: valuable properties of tablet, expanded assortment of medicinal formulations of opioid analgesics.

19 cl, 4 tbl, 4 ex

FIELD: medicine, endocrinology.

SUBSTANCE: the present innovation deals with preventing diabetes mellitus and its aftereffects. It is suggested to apply sibutramin and its analogs to decrease non-susceptibility to insulin in diabetes-free patients, prevent decreased tolerance to glucose and decrease the quantity of introduced insulin in diabetes-suffering patients and normalize body weight, as well.

EFFECT: higher efficiency of application.

28 cl, 3 dwg, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of benzene of the formula (I): wherein A represents a group taking among the following groups: -C≡C-, -CH=CH-, -CH2-CH2; n = 1 or 2; X represents hydrogen, chlorine or fluorine atom or methyl or methoxy-group; Y represents hydrogen, chlorine or fluorine atom; R1 represents cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with methyl group, phenyl group monosubstituted or disubstituted with fluorine or chlorine atom or methoxy-group, cycloheptyl, tert.-butyl, dicyclopropylmethyl, 4-tetrahydropyranyl or 1- or 2-adamantyl, or adamantine-2-ol group; or R1 represents phenyl group and in this case X and Y both represents chlorine atom; R2 represents hydrogen atom or (C1-C4)-alkyl group; R3 represents (C5-C7)-cycloalkyl, and salts of these compounds formed by addition of pharmaceutically acceptable acids, and their solvates and hydrates also. Also, invention relates to methods for preparing compounds of the formula (I) and to pharmaceutical composition able to interact with receptors sigma-2 based on these compounds. Invention provides preparing new compounds and medicinal agents based on thereof for treatment of autoimmune states, disturbance on heart contraction frequency and control against proliferation of tumor cells.

EFFECT: improved preparing methods, valuable medicinal properties of compositions.

18 cl, 14 tbl, 78 ex

FIELD: medicine.

SUBSTANCE: method involves administering typical tricyclic antidepressants combined with selective reverse serotonin capture inhibitors. Anxious version of subpsychotic level depressive syndrome of endogenous genesis being treated, intravenous drop-by-drop infusion of 2.-4.0 ml of 1% amitriptiline solution per 200 ml of physiologic saline is applied in 12-14 procedures combined with selective reverse serotonin capture inhibitor given per os, Zoloft is per os administered as the inhibitor at a dose of 50-100 mg. Then, supporting Zoloft therapy is applied at a dose of 100 mg during 3 months. Atypic version of depressive syndrome of subpsychotic level and endogenous genesis is treated with intravenous drop-by-drop infusion of 1.25% Melipramine solution at a dose of 2.0-4.0 ml per 200 ml of power supply source in 12-14 infusions combined with a reverse serotonin capture inhibitor. Paxyl is taken at a peroral dose of 40-60 mg as the inhibitor. Then, supporting Paxyl therapy is applied at a dose of 40-60 mg during 3 months.

EFFECT: enhanced effectiveness of treatment; reduced risk of complications; accelerated depressive syndrome relief.

FIELD: medicine.

SUBSTANCE: the suggested transdermal therapeutic system (TTS) is indicated for percutaneous injection of tolterodin for several days. It is, also, described the method for its manufacturing. The suggested TTS is being a self-gluing lamellar matrix structure that contains methacrylate copolymer including ammonium groups, at least, one plastifier and up to 25 weight% tolterodin. TTS is of good tolerance by skin and is of good physical and chemical stability at prolonged storage and application, it, also, has got good adhesive properties and can provide the penetration of maximal quantity of active substance through skin.

EFFECT: higher efficiency of application.

8 cl, 2 dwg, 3 ex, 3 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to new acid-additive nitrate salts of compounds taken among salbutamol, cetirizine, loratidine, terfenadine, emedastine, ketotifen, nedocromil, ambroxol, dextrometorphan, dextrorphan, isoniazide, erythromycin and pyrazinamide. Indicated salts can be used for treatment of pathology of respiratory system and elicit an anti-allergic, anti-asthmatic effect and can be used in ophthalmology also. Indicated salts have less adverse effect on cardiovascular and/or gastroenteric systems as compared with their non-salt analogues. Also, invention proposes pharmaceutical compositions for preparing medicinal agents for treatment of pathology of respiratory system and comprising above indicated salts or nitrate salts of metronidazol or aciclovir.

EFFECT: improved and valuable properties of compounds.

6 cl, 5 tbl, 19 ex

FIELD: medicine.

SUBSTANCE: method involves applying fractal introduction of 0.2 mg/kg MT calypsol and 0.4 mcg/kg MT fentanyl every 10 min during operation. Additional local spinal cord root irrigation with 2% lidocaine solution at maximum traumatic operation moment.

EFFECT: enhanced effectiveness of treatment; preserved spontaneous patient respiration.

1 tbl

FIELD: organic chemistry, medicine.

SUBSTANCE: invention reports about preparing new substituted derivatives of 2-dialkylaminoalkylbiphenyl of the general formula (I):

wherein n = 1 or 2; R1 means cyano-group (CN), nitro-group (NO2), SO2CH3, SO2CF3, NR6aR7a, acetyl or acetamidyl; R2 means hydrogen atom (H), fluorine atom (F), chlorine atom (Cl), bromine atom (Br), cyano-group (CN), nitro-group (NO2), CHO, SO2CH3, SO2CF3, OR6, NR6R7, (C1-C6)-alkyl, acetyl or acetamidyl being alkyl can comprise one or more similar or different substitutes taken among halogen atom or hydroxy-group; or R1 and R mean in common group -OCH2O, -OCH2CH2O, CH=CHO, CH=C(CH3)O or CH=CHNH; R3 means H, F, Cl, Br, CN, NO2, CHO, SO2CH3, SO2CF3, OR6, NR6R7, (C1-C6)-alkyl, acetyl or acetamidyl being alkyl can comprise one or more similar or different substitutes taken among halogen atom or hydroxy-group; R4 and R5 have similar or different values and mean hydrogen atom (H) or unsubstituted (C1-C6)-alkyl; R6 and R7 have similar or different values and mean hydrogen atom (H) or unsubstituted (C1-C6)-alkyl; R6a means hydrogen atom (H) or unsubstituted (C1-C6)-alkyl; R7a means unsubstituted (C1-C6)-alkyl as their bases and/or salts of physiologically acceptable acids, with exception of compound representing 4-chloro-2'-dimethylaminomethylbiphenyl-2-carbonitrile and to a method for their preparing. Derivatives of 2-dialkylaminoalkylbiphenyl can be used in medicine for treatment or prophylaxis of pains, inflammatory and allergic responses, depressions, narcomania, alcoholism, gastritis, diarrhea, enuresis, cardiovascular diseases, respiratory ways diseases, cough, psychiatry disorders and/or epilepsy.

EFFECT: valuable medicinal properties of compounds.

13 cl, 2 tbl, 43 ex

FIELD: obstetrics and gynecology.

SUBSTANCE: over a 2-5 day period, 2.0 ml of Ginipral is administered once a day intravenously in a drop-by-drop manner followed by intravenously drop-by-drop administered 30-40 min later 2.0 ml of Instenone and, in the evening, 1 dragee Instenone orally. Afterwards, Instenone and Ginipral are administered orally: the former in dose of 1 dragee thrice a day with meal and the latter in dose of 1 pellet four times a day after meal until symptoms of the risk of prevention of pregnancy disappear.

EFFECT: prolonged pregnancy and prevented premature birth, which favors reduced irritation, normalized tonus, contractive activity of uterus, and improved psychic and emotional state of women.

2 ex